Search research articles
Contact Us
Filters
Showing results (1-10 of 36) with videos related to
Page
of 4
Sort By:
Pharmaceutical Medicine
|
August 22, 2017
Different Weights of the Evidence-Based Medicine Triad in Regulatory, Health Technology Assessment, and Clinical Decision Making
Evelyn Schlegl, Pierre Ducournau, Jörg Ruof
Drugs in R&D
|
August 20, 2015
Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
Jörg Ruof, Olivier Flückiger, Niko Andre
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 28, 2014
Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach
Jörg Ruof, Charalabos-Markos Dintsios, Friedrich Wilhelm Schwartz
Pharmacoeconomics
|
April 17, 2003
Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus
Andreas Maetzel, Jörg Ruof, Melva Covington, et al.
Expert Opinion on Pharmacotherapy
|
August 28, 2004
Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis
Sonja Merkesdal, Jörg Ruof, Thomas Mittendorf, et al.
Clinical Drug Investigation
|
June 15, 2007
Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients
Jörg Ruof, Alexander Dusek, Michael DeSpirito, et al.
BMC Health Services Research
|
November 16, 2016
Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases
Thomas Staab, Georg Isbary, Volker E Amelung, et al.
Journal of Market Access & Health Policy
|
November 26, 2024
Technology Assessment vs. Technology Appraisal-How to Strengthen the Science/Value Dichotomy with EU HTA?
Sandro Gsteiger, Heiner C Bucher, James Ryan, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 8, 2009
Indirect medical costs in the first 3 years of rheumatoid arthritis: comparison of current methodological approaches
Sonja Merkesdal, Jörg Ruof, Thomas Mittendorf, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen
|
December 26, 2015
[The influence of framework conditions for integrated care programs on their potential of evaluation]
Svenja Jacobs, Justyna Hartmann, Sveja Eberhard, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 36) with videos related to
Sort By:
Page
of 4
Pharmaceutical Medicine
|
August 22, 2017
Different Weights of the Evidence-Based Medicine Triad in Regulatory, Health Technology Assessment, and Clinical Decision Making
Evelyn Schlegl, Pierre Ducournau, Jörg Ruof
Drugs in R&D
|
August 20, 2015
Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
Jörg Ruof, Olivier Flückiger, Niko Andre
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 28, 2014
Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach
Jörg Ruof, Charalabos-Markos Dintsios, Friedrich Wilhelm Schwartz
Pharmacoeconomics
|
April 17, 2003
Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus
Andreas Maetzel, Jörg Ruof, Melva Covington, et al.
Expert Opinion on Pharmacotherapy
|
August 28, 2004
Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis
Sonja Merkesdal, Jörg Ruof, Thomas Mittendorf, et al.
Clinical Drug Investigation
|
June 15, 2007
Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients
Jörg Ruof, Alexander Dusek, Michael DeSpirito, et al.
BMC Health Services Research
|
November 16, 2016
Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases
Thomas Staab, Georg Isbary, Volker E Amelung, et al.
Journal of Market Access & Health Policy
|
November 26, 2024
Technology Assessment vs. Technology Appraisal-How to Strengthen the Science/Value Dichotomy with EU HTA?
Sandro Gsteiger, Heiner C Bucher, James Ryan, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 8, 2009
Indirect medical costs in the first 3 years of rheumatoid arthritis: comparison of current methodological approaches
Sonja Merkesdal, Jörg Ruof, Thomas Mittendorf, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen
|
December 26, 2015
[The influence of framework conditions for integrated care programs on their potential of evaluation]
Svenja Jacobs, Justyna Hartmann, Sveja Eberhard, et al.
Page
of 4